As leukemia-initiating AML cells can reside in the CD34+CD38+ compartment, treatment with the recombinant antibody daratumumab against CD38 inhibits mitochondrial transfer to AML blasts, inhibiting the leukemia growth (Mistry et al., 2019). The gene discussed is CD38; the disease is acute myeloid leukemia.